drugset / Trial / NCT05461339
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
Phase 3
Active not recruiting
488 enrolled
BioDlink Biopharm Co., Ltd.
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients. The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).
Timeline
- Start
- 2022-06-28
- Primary completion
- 2024-09-20
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | TAB014 | Monoclonal antibody | 1.25 mg | Intravitreal |